Skip to content

Routine Or Selective Application of a Face Mask for Preterm Infants at Birth: the ROSA Trial

A Randomised Trial of Routine or Selective Application of a Face Mask for Preterm Infants at Birth

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04500353
Acronym
ROSA
Enrollment
201
Registered
2020-08-05
Start date
2020-10-11
Completion date
2023-05-09
Last updated
2023-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Continuous Positive Airway Pressure, Infant, Premature, Diseases, Positive-Pressure Respiration, Respiratory Distress Syndrome, Newborn, Resuscitation

Brief summary

International guidelines recommend giving positive pressure ventilation (PPV) by face mask to newborns who do not breathe or have a slow heart rate at birth. Preterm infants are at high risk of developing respiratory distress syndrome (RDS) and many are treated with continuous positive airway pressure (CPAP) in the neonatal intensive care unit (NICU). Though the majority of preterm infants breathe spontaneously at birth, many clinicians routinely apply a face mask to preterm infants shortly after birth in the delivery room (DR) to give them CPAP. However, applying a face mask may inhibit spontaneous breathing in newborns. In this study, premature babies will be randomly assigned to have a face mask routinely applied for CPAP shortly after birth; or to have a face mask selectively applied only for PPV if they are not breathing or have a slow heart beat in the first 5 minutes of life, or for CPAP if they have signs of respiratory distress after 5 minutes. The investigators will determine whether fewer participants who have the mask selectively applied receive PPV in the DR.

Detailed description

Newly born babies have fluid-filled lungs that they must quickly aerate after birth. Compared to infants born at term, preterm babies have greater difficulty in establishing and maintaining aeration of their lungs; this leaves them at increased risk of developing respiratory distress syndrome (RDS). Infants who develop RDS are treated with nasal continuous positive airway pressure (CPAP), and may progress to treatment with surfactant and mechanical ventilation, in the Neonatal Intensive Care Unit (NICU). The Neonatal Task Force of the International Liaison Committee on Resuscitation (ILCOR) makes recommendations on the treatment of infants at birth. ILCOR recommends assessing the breathing and heart rate (HR) of all newborns, and: 1. Giving positive pressure ventilation (PPV) to babies who have a HR \< 100bpm, gasping or apnoea 2. Considering giving CPAP to babies who have laboured breathing or persistent cyanosis Most preterm infants breathe spontaneously at birth. Despite this, the majority of preterm infants have a facemask applied for respiratory support immediately after birth, usually before the HR has been determined. Clinicians presumably do this to give early support to infants they believe are at high risk of developing RDS in an attempt to prevent or lessen the severity of the disease. There is little evidence that giving preterm infants prophylactic nasal CPAP may be superior to supportive care with oxygen. A study that compared nasopharyngeal CPAP to supportive care with oxygen performed before antenatal steroids were routinely given found no difference in the rate of development of RDS with the application of CPAP. Two more recent studies did not show that early application of nasal CPAP reduced the rate of intubation or treatment with surfactant. In these studies CPAP was given by nasal prongs and was started at 15 - 30 minutes of life, not immediately with a facemask. There is no evidence that facemask CPAP immediately after birth prevents or reduces the severity of RDS. Application of a face mask has been demonstrated to inhibit spontaneous breathing in many term infants. Cold gas flow, such as that provided by a T-piece, can inhibit spontaneous breathing in term infants. Application of a face mask for breathing support appears to inhibit breathing in a greater proportion of preterm infants. Considerable force is applied to the head when face mask PPV is given to a mannequin in the supine position. Routinely applying a face mask for respiratory support may be unnecessary in many premature babies. It may inhibit their spontaneous breathing and result in them receiving facemask PPV more frequently in the DR. It may also affect how well they breathe in the first day of life and increase the rate of treatment with nasal CPAP in the NICU. METHODS RANDOMISATION AND GROUP ASSIGNMENT Participants will be randomly assigned to SELECTIVE or ROUTINE groups in a 1:1 ratio. The group assignment schedule will be generated in blocks of 4 using a random number table, and will be stratified by gestational age (23 - 27, 28 - 31+6). It will be kept on a concealed from investigators and treating clinicians. Group assignment will be written on cards and placed in sequentially numbered, sealed, opaque envelopes. Infants of multiple gestations will be randomised as individuals. The envelopes will be contained in 2 boxes for GA strata and kept in the NICU. The next envelope in the sequence will be taken from the appropriate box and brought to the DR, where it will be opened just before delivery. MASKING It is not possible to mask caregivers to group assignment. INTERVENTIONS ALL INFANTS Infants in both groups will have their umbilical cord clamped at or after 1 minute of age; they will not have a mask applied for respiratory support during this time. Infants will then be transferred to resuscitaire, placed supine under radiant heat and have a hat applied. All infants will be placed in polyethylene bag. A pulse oximeter will be placed on the right wrist. A T-piece device (Neopuff, Fisher & Paykel Healthcare, Auckland NZ; or Dräger Resuscitaire (Drager healthcare, Lübeck, Germany) and round face mask (Fisher & Paykel Healthcare, Auckland NZ) of appropriate size for the baby will be used to give respiratory support to infants in both groups. The T-piece will have gas flow set at 8 - 10 L/min, with settings PEEP 6cmH2O, and PIP 25cmH2O. There will be an air/oxygen blender in the circuit and the FiO2 will be initially set at 30%. The FiO2 will not be adjusted before 5 minutes of age. SELECTIVE GROUP Infants assigned to the SELECTIVE group will be placed supine to breathe spontaneously. If SpO2 \< 70% at 5 minutes and their respiratory effort is good, they will be given give free flow oxygen (i.e. the mask will be placed in front of, but not directly in contact with, the infant's face). The FiO2 may be increased at 1 minute intervals thereafter, aiming for SpO2 ≥ 90% at 10 minutes of life. Infants in the SELECTIVE group will have mask PPV if they are apnoeic or have HR \< 100bpm at any time in the DR. Clinicians may consider applying facemask to give CPAP if the infants breathing is laboured (i.e. there are signs of respiratory distress - grunting, intercostal/subcostal/sternal recessions) after 5 minutes of age. ROUTINE GROUP Infants assigned to the ROUTINE group will be placed supine on the resuscitaire and have facemask CPAP applied as soon as possible after they arrive. If SpO2 \< 70% at 5 minutes, the FiO2 may be increased at 1 minute intervals, aiming for SpO2 ≥ 90% at 10 minutes of life. Infants in the ROUTINE group will have facemask PPV if they are apnoeic or have HR \< 100bpm at any time in the DR. Mask respiratory support may be withdrawn as and when desired by clinical staff. RESUCE TREATMENT All other treatments - i.e. endotracheal intubation for PPV, chest compressions, adrenaline, volume - w ill be given at the discretion of the treating clinicians and in accordance with ILCOR recommendations. SAMPLE SIZE ESTIMATION To show a reduction in the proportion of babies receiving PPV with routine application from 60% to 40% with selective application with 80% power and α of 0.05, the investigators need to recruit 200 infants.

Interventions

OTHERFace mask application for CPAP and/or PPV delivery

Face mask application for CPAP and/or PPV delivery

Sponsors

University College Dublin
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Masking of caregivers not feasible due to the nature of the intervention

Intervention model description

Randomised parallel group study

Eligibility

Sex/Gender
ALL
Age
0 Minutes to 5 Minutes
Healthy volunteers
No

Inclusion criteria

* Born before 32 weeks gestational age by best obstetric estimate

Exclusion criteria

* Infants with major congenital anomalies

Design outcomes

Primary

MeasureTime frameDescription
The proportion of participants who receive face mask PPV in the delivery room DRWithin 30 minutes of birthThe proportion of participants who receive face mask positive pressure ventilation (PPV) in the delivery room (DR)

Secondary

MeasureTime frameDescription
The proportion of participants who receive face mask CPAP in the first 5 minutes of life5 minutesThe proportion of participants who receive face mask (continuous positive airway pressure) CPAP in the first 5 minutes of life
The proportion of participants who receive face mask PPV in the first 5 minutes of life5 minutesThe proportion of participants who receive face mask PPV in the first 5 minutes of life
HR at 5 minutes of life5 minutesHeart rate (HR) at 5 minutes of life
SpO2 at 5 minutes of life5 minutesOxygen saturation (SpO2) at 5 minutes of life
The proportion of participants who receive face mask CPAP in the DRWithin 30 minutes of birthThe proportion of participants who receive face mask CPAP in the DR
Duration of PPV in the DRWithin 30 minutes of birthDuration of PPV in the DR
The proportion of participants who are intubated in the DRWithin 30 minutes of birthThe proportion of participants who are intubated in the DR
The proportion of participants who receive chest compressions in the DRWithin 30 minutes of birthThe proportion of participants who receive chest compressions in the DR
The proportion of participants who receive volume in the DRWithin 30 minutes of birthThe proportion of participants who receive volume in the DR
The proportion of participants who receive adrenaline in the DRWithin 30 minutes of birthThe proportion of participants who receive adrenaline in the DR
Maximum FiO2 in the DRWithin 20 minutes of birthMaximum fraction of inspired oxygen (FiO2) in the DR
The proportion of participants who receive endotracheal ventilation in NICUWithin one monthThe proportion of participants who receive endotracheal ventilation in NICU
Apgar score at 10 minutes10 minutesApgar score at 10 minutes (scale 0 -10, higher scores indicate better outcome)
Respiratory support in transport to NICUWithin 45 minutes of birthRespiratory support in transport to the neonatal intensive care unit (NICU)
The proportion of participants who receive NCPAP in NICUWithin one monthThe proportion of participants who receive nasal CPAP in NICU
The proportion of participants who receive surfactant treatmentWithin one monthThe proportion of participants who receive surfactant treatment
The proportion of participants who have a pneumothorax drainedWithin one monthThe proportion of participants who have a pneumothorax drained
The proportion of participants who survive free of BPDDay 28 of lifeThe proportion of participants who are alive and not receiving respiratory support or supplemental oxygen on day 28 of life
The proportion of participants who receive survive free of CLD36 weeks correctedThe proportion of participants who are alive and not receiving respiratory support or supplemental oxygen at 36 weeks corrected age
The proportion of participants who receive postnatal steroidsThrough study completion, an average of 2-3 months in survivorsThe proportion of participants who receive postnatal steroids
The proportion of participants who receive home oxygen therapyThrough study completion, an average of 2-3 months in survivorsThe proportion of participants who receive home oxygen therapy
The proportion of participants who die before hospital dischargeThrough study completion, an average of 2-3 months in survivorsThe proportion of participants who die before hospital discharge
Apgar score at 5 minutes5 minutesApgar score at 5 minutes (scale 0 -10, higher scores indicate better outcome)

Countries

Ireland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026